

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re United States Patent Application of:)	Docket No.:	014811-188.74
Applicant: EKWURIBE et al.)	Examiner:	Jeffrey E. Russel
)		
Application No.: 10/018,879)	Art Group:	1654
Date Filed: August 5, 2002)	Confirmation No.:	8724
U.S. Patent No.: 7,169,889 B1)	Customer No.:	24,239
Date Issued: January 30, 2007)		
Title: INSULIN PRODRUGS)		
HYDROLYZABLE IN VIVO)		
TO YIELD PEGLYLATED)		
INSULIN)		

**SUBMISSION OF CERTIFICATE OF CORRECTION UNDER THE PROVISIONS OF
37 CFR § 1.322 AND 35 U.S.C. § 254 FOR U.S. PATENT NO. 7,169,889 B1**

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

Enclosed is a Certificate of Correction submitted under the provisions of 35 U.S.C. §254, to correct errors of the Patent and Trademark Office in the printing of the above-identified U.S. Patent.

In addition to the errors of the Patent and Trademark Office, a review of the patent has revealed the presence of errors attributable to the original application, which however are of a minor and self-evident character, as listed below:

Column 11, Line 25	delete "amphiphilicity" and insert in place thereof -- amphicity--
Column 13, Line 17	delete "may" and insert in place thereof -- many--
Column 13, Line 52	"useful in as components" should be --useful as components--
Column 14, Line 31	delete "aids" and insert in place thereof --acids--

Column 18, Line 35 delete "peptidominetic" and insert in place thereof --peptidomimetic--

Column 23, Line 60 "and oil" should be --an oil--

Column 25, Line 44: "pancrectectotized diabetic" should be --pancreteactomized diabetic--

While these errors are not of a serious enough nature to warrant a Certificate of Correction, the patentees nevertheless wish to bring same to the attention of the Patent and Trademark Office, so that same are made of record in the file of this patent.

Respectfully submitted,



Marianne Fuierer

Reg. No. 39983

Attorney for Applicant(s)/Patentee(s)

Moore & Van Allen PLLC

Suite 500

430 Davis Drive

PO Box 13706

Research Triangle Park, NC 27709

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

(Also Form PTO-1050)

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO: 7,169,889 B1

DATED: January 30, 2007

INVENTOR(S): EKWURIBE et al.

It is certified that error appears in the above-identified patent and that said Letters Patent are hereby corrected as shown below:

Column 5, Line 43: "emulsion of" should be --emulsion or --

Column 8, Line 39: "mitigate treat" should be --mitigate, treat --

Column 8, Line 47: "reduce the seventy" should be ---reduce the severity--

Column 11, Line 3: "H L₈ bond" should be ---H-L₈ bond---

Column 13, Line 67: "functional, equivalent" should be ---functional equivalent---

Column 14, Line 4: "praline" should be --proline--

Column 17, Line 4: "in a DH-S or D H' configuration" should be -- in a D-H-S or D-H-S-H' configuration--

Column 17, Line 8: "the OH configuration" should be --the D-H configuration--

Column 17, Line 32: "Drug-oligomer Conjugates" should be
--Drug-oligomer Conjugates--

Column 17, Line 50: "orsequencing" should be ---or sequencing--

Column 19, Line 50: "CH₃(CH₂)₆CONHCH₂CH₂(OC₂H₄)OCO-Peptide" should be
--CH₃(CH₂)₆CONHCH₂CH₂(OC₂H₄)OCO-Peptide--

Column 21, Line 38: "acid, alkyl₁₋₂₆" should be ---acid, alkyl₁₋₂₆--

Column 26, Line 49: "Laurate PEGs" should be --Laurate PEG₃--

Column 26, Line 61: "perstaitic pump" should be --perstaltic pump--

Column 27, Line 39: "Capmul MCM" should be --Capmul MCM--

Column 28, Line 18: "PEG 9" should be --PEG₉--

Column 28, Line 22: "Insulin PEGg Oleate" should be --Insulin PEG₉ Oleate--

MAILING ADDRESS OF SENDER:

PATENT NO. 7,169,889 B1

Marianne Fuierer
Moore & Van Allen PLLC
Suite 500
430 Davis Drive
PO Box 13706
Research Triangle Park, NC 27709

No. of additional copies 0



Burden Hour Statement: This form is estimated to take 1.0 hour to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.